- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02826057
The Complement Lectin Pathway After Cardiac Arrest
The Complement Lectin Pathway in Patients Resuscitated After Cardiac Arrest
This study includes comatose survivors of out-of-hospital cardiac arrest treated with 24 hours or 48 hours of targeted temperature management.
The overall aim is to evaluate the importance of plasma complement protein concentrations in patients resuscitated after out-of-hospital cardiac arrest and treated with 24 hours or 48 hours of targeted temperature management.
The specific aim is to evaluate:
- the concentration of plasma lectin pathway proteins the first, second and third day after cardiac arrest
- the relation between concentration of plasma lectin pathway proteins and mortality
- if prolonged targeted temperature management influences the concentration of plasma lectin pathway proteins
This study is a sub-study to the trial entitled: "Time-differentiated targeted temperature management (TTH48) (ClinicalTrials.gov Identifier: NCT01689077)"
The following Complement Lectin Pathway proteins will be measured: Mannan-Binding-Lectin, M-ficolin, H-ficolin, CL-L1, MASP-1, MASP-2, MASP-3, MAp19 and MAp44.
Studieöversikt
Status
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Aarhus, Danmark, 8000
- Department of Biomedicine, Aarhus University
-
Aarhus, Danmark, 8200
- Department of Anesthesiology and Intensive Care, Aarhus University Hospital
-
Aarhus, Danmark, 8200
- Department of Clinical Biochemistry, Aarhus University Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Out-of-Hospital Cardiac Arrest of presumed cardiac cause
- Return of spontaneous circulation (ROSC)
- Glasgow Coma Score < 8
- Age > 18 years and < 80 years
Exclusion Criteria:
- > 60 minutes from the circulatory collapse to ROSC
- Time interval > 4 hours from cardiac arrest to initiation of targeted temperature management
- Terminal illness
- Coagulation disorder
- Unwitnessed asystolia
- Cerebral performance category 3-4 before the cardiac arrest
- Severe persistent cardiogenic shock
- Pregnancy
- Persistent cardiogenic shock (systolic bloodpressure < 80 despite inotropic treatment)
- New apoplexy or cerebral hemorrhage
- Lack of consent from the relatives
- Lack of consent from the general practitioner
- Lack of consent from the patient
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Grundläggande vetenskap
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: 24 hour of targeted temperature management
Patients resuscitated after cardiac arrest and treated with 24 hours of targeted temperature management (33 degree Celsius)
|
|
Experimentell: 48 hour of targeted temperature management
Patients resuscitated after cardiac arrest and treated with 48 hours of targeted temperature management (33 degree Celsius)
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
MASP-2 concentration in plasma
Tidsram: 48 hours
|
48 hours
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
MASP-2 concentration in plasma
Tidsram: 24 hours, 48 hours and 72 hours
|
24 hours, 48 hours and 72 hours
|
|
MASP-2 concentration in plasma
Tidsram: 24 hours, 48 hours, 72 hours
|
MASP-2 concentration in plasma compared with 30-day mortality
|
24 hours, 48 hours, 72 hours
|
MASP-2 concentration in plasma
Tidsram: 24 hours to 72 hours
|
24 hours to 72 hours
|
|
MASP-1 concentration in plasma
Tidsram: 24 hours, 48 hours and 72 hours
|
24 hours, 48 hours and 72 hours
|
|
MASP-1 concentration in plasma
Tidsram: 24 hours to 72 hours
|
24 hours to 72 hours
|
|
MASP-1 concentration in plasma
Tidsram: 24 hours, 48 hours, 72 hours
|
MASP-1 concentration in plasma compared with 30-day mortality
|
24 hours, 48 hours, 72 hours
|
MASP-3 concentration in plasma
Tidsram: 24 hours, 48 hours and 72 hours
|
24 hours, 48 hours and 72 hours
|
|
MASP-3 concentration in plasma
Tidsram: 24 hours to 72 hours
|
24 hours to 72 hours
|
|
MASP-3 concentration in plasma
Tidsram: 24 hours, 48 hours, 72 hours
|
MASP-3 concentration in plasma compared with 30-day mortality
|
24 hours, 48 hours, 72 hours
|
Mannan-Binding-Lectin concentration in plasma
Tidsram: 24 hours, 48 hours and 72 hours
|
24 hours, 48 hours and 72 hours
|
|
Mannan-Binding-Lectin concentration in plasma
Tidsram: 24 hours to 72 hours
|
24 hours to 72 hours
|
|
Mannan-Binding-Lectin concentration in plasma
Tidsram: 24 hours, 48 hours, 72 hours
|
Mannan-Binding-Lectin concentration in plasma compared to 30-day mortality
|
24 hours, 48 hours, 72 hours
|
MAp44 concentration in plasma
Tidsram: 24 hours, 48 hours and 72 hours
|
24 hours, 48 hours and 72 hours
|
|
Map44 concentration in plasma
Tidsram: 24 hours to 72 hours
|
24 hours to 72 hours
|
|
MAp44 concentration in plasma
Tidsram: 24 hours, 48 hours, 72 hours
|
MAp44 concentration in plasma compared with 30-day mortality
|
24 hours, 48 hours, 72 hours
|
MAp19 concentration in plasma
Tidsram: 24 hours, 48 hours and 72 hours
|
24 hours, 48 hours and 72 hours
|
|
MAp19 concentration in plasma
Tidsram: 24 hours to 72 hours
|
24 hours to 72 hours
|
|
MAp19 concentration in plasma
Tidsram: 24 hours, 48 hours, 72 hours
|
MAp19 concentration in plasma compared with 30-day mortality
|
24 hours, 48 hours, 72 hours
|
H-ficolin concentration in plasma
Tidsram: 24 hours, 48 hours and 72 hours
|
24 hours, 48 hours and 72 hours
|
|
H-ficolin concentration in plasma
Tidsram: 24 hours to 72 hours
|
24 hours to 72 hours
|
|
H-ficolin concentration in plasma
Tidsram: 24 hours, 48 hours, 72 hours
|
H-ficolin concentration in plasma compared with 30-day mortality
|
24 hours, 48 hours, 72 hours
|
M-ficolin concentration in plasma
Tidsram: 24 hours, 48 hours and 72 hours
|
24 hours, 48 hours and 72 hours
|
|
M-ficolin concentration in plasma
Tidsram: 24 hours to 72 hours
|
24 hours to 72 hours
|
|
M-ficolin concentration in plasma
Tidsram: 24 hours, 48 hours, 72 hours
|
M-ficolin concentration in plasma compared with 30-day mortality
|
24 hours, 48 hours, 72 hours
|
CL-L1 concentration in plasma
Tidsram: 24 hours, 48 hours and 72 hours
|
24 hours, 48 hours and 72 hours
|
|
CL-L1 concentration in plasma
Tidsram: 24 hours to 72 hours
|
24 hours to 72 hours
|
|
CL-L1 concentration in plasma
Tidsram: 24 hours, 48 hours, 72 hours
|
CL-L1 concentration in plasma compared with 30-day mortality
|
24 hours, 48 hours, 72 hours
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 12345 (Danish Center for Healthcare Improvements)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Hjärtstopp utanför sjukhuset
-
University of AarhusAvslutadHjärtstopp | Hypotermi | Post Cardiac Arrest SyndromeDanmark
-
Russian Federation of Anesthesiologists and ReanimatologistsRekryteringPost Cardiac Arrest SyndromeRyska Federationen
-
AO Clinical Investigation and Publishing DocumentationRekryteringOrbitalfrakturer | Blow Out Fracture of OrbitSverige, Förenta staterna, Nederländerna, Rumänien, Spanien, Tyskland, Pakistan, Qatar, Ryska Federationen, Serbien, Sydafrika, Schweiz
-
Assiut UniversityHar inte rekryterat ännu1- Hemodynamisk fenotypning av out-of-proportion PH för att vägleda olika terapeutiska linjerEgypten
-
University Medical Center GroningenOkändAkutsjukvård | Hjärtstopp utanför sjukhuset | Post Cardiac Arrest Syndrome
-
University of FlorenceSandro Gelsomino; Edvin Prifti; Francesco Cabrucci; Marco Bugetti; Orlando Parise och andra samarbetspartnersRekryteringKardiogen chock | Extrakorporeal membransyresättningskomplikation | Post-hjärtkirurgi | Utomkroppsligt livstöd | Post Cardiac Arrest SyndromeItalien
-
Christian HassagerAvslutadSystemiskt inflammatoriskt svarssyndrom | Hjärtstopp | Hjärtstopp utanför sjukhuset | Neurologisk skada | Hjärtstillestånd med lyckad återupplivning | Post Cardiac Arrest SyndromeDanmark